Analyst Price Target is $26.50
▲ +160.83% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rezolute in the last 3 months. The average price target is $26.50, with a high forecast of $30.00 and a low forecast of $21.00. The average price target represents a 160.83% upside from the last price of $10.16.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Rezolute.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.